Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 31, 2021
Reporting Period: Event date of March 31, 2021
The filing reports the entry into a material definitive agreement regarding the company's credit facilities.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, or liquidity metrics. It focuses exclusively on the terms of a debt agreement amendment.
Material Changes Versus Prior Period
On March 31, 2021, the company entered into a Fourth Amendment to its Credit Agreement with Silicon Valley Bank (SVB). The amendment modifies the existing term loan and revolving credit facility as follows:
- Amortization Start Date: Postponed from March 1, 2021, to July 1, 2021.
- Maturity Date: Shortened from March 1, 2024, to February 1, 2024.
- Payment Schedule: Decreased from 36 monthly principal installments to 32 monthly principal installments.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk disclosed relates to the modification of debt repayment terms, specifically the acceleration of the maturity date and the reduction in the number of amortization periods, which may impact future cash flow requirements.
Investor Verification Checklist
- Verify the full text of the Fourth Amendment to Credit Agreement (Exhibit 10.1) for covenants and interest rate implications.
- Confirm the impact of the shortened maturity date (February 1, 2024) on the company's liquidity planning.
- Review the company's most recent 10-Q or 10-K for current debt balances and cash flow status to assess the ability to meet the new amortization schedule starting July 1, 2021.